Human immunodeficiency virus (HIV)-1 infection is a leading cause of morbidity and mortality around the world, with many new infections occurring daily and the development of a safe and effective HIV vaccine is a critically important global health priority. An effective vaccine for HIV remains elusive and the development of an effective vaccine against HIV is the long-term solution to this problem. The success of the RV144 Thai HIV-1 efficacy trail showing 31 % of efficacy has given hope that indeed a protective HIV vaccine can be developed. The goal of this program is to generate novel vaccination approaches that enhance the quantity as well as quality of anti-viral cellular and humoral responses using CD40L as an adjuvant and MVA delta4 as a boosting vector. The overall objectives for this Core are to provide the required experimental animals and support services needed to facilitate the AIDS vaccine development studies proposed in projects 2 and 3. This will be accomplished by the following specific aims: 1. To select and provide male rhesus macaques from the Yerkes breeding colony suitable for the research aims of the macaque trials of the program project. 2. To provide exceptional animal care, veterinary care, and environmental enrichment. 3. To perform vaccine administrations to measure immunogenicity. 4. To perform sample collections including the collection of various tissue samples and secretions for in vitro studies. 5. To perform repeated rectal SHIV challenges on immunized and unimmunized control animals to test vaccine efficacy. 6. To perform periodic physical examinations and blood collections from the experimental animals. 7. To perform complete gross and histologic evaluation of any experimental animals that dies or sacrificed during the course of the study.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI109633-05
Application #
9427965
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Jones, Andrew T; Chamcha, Venkateswarlu; Kesavardhana, Sannula et al. (2018) A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. J Virol 92:
Kelley, C F; Kraft, C S; de Man, T Jb et al. (2017) The rectal mucosa and condomless receptive anal intercourse in HIV-negative MSM: implications for HIV transmission and prevention. Mucosal Immunol 10:996-1007
Mylvaganam, Geetha H; Rios, Daniel; Abdelaal, Hadia M et al. (2017) Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection. Proc Natl Acad Sci U S A 114:1976-1981
Chea, Lynette Siv; Amara, Rama Rao (2017) Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models. Expert Rev Vaccines 16:973-985
Kannanganat, Sunil; Wyatt, Linda S; Gangadhara, Sailaja et al. (2016) High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5?-Restrictive Macaques. J Immunol 197:3586-3596
Velu, Vijayakumar; Mylvaganam, Geetha Hanna; Gangadhara, Sailaja et al. (2016) Induction of Th1-Biased T Follicular Helper (Tfh) Cells in Lymphoid Tissues during Chronic Simian Immunodeficiency Virus Infection Defines Functionally Distinct Germinal Center Tfh Cells. J Immunol 197:1832-42
Cartwright, Emily K; Spicer, Lori; Smith, S Abigail et al. (2016) CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy. Immunity 45:656-668